Kvíz spojený s průvodcem · Střední úroveň
AI in Liver Disease and Hepatology Quiz
Tests liver pathology scoring, ultrasound research, transplant-risk models, FDA qualification scope, and professional review.
Otázka 1 z 8
Pro jaké nastavení FDA kvalifikovala AIM-NASH jako nástroj pro vývoj léků?
Náhled každé otázky8 otázky
Odpovědi a vysvětlení se zobrazují, jak budete v kvízu.
- Pro jaké nastavení FDA kvalifikovala AIM-NASH jako nástroj pro vývoj léků?
- Diagnosing all liver diseases from a blood test
- Setting transplant priority in every country
- Scoring liver-biopsy features in MASH clinical trials
- Replacing liver biopsy with ultrasound
- Kdo dělá konečnou interpretaci skóre biopsie AIM-NASH?
- The AI tool alone
- The pathologist after reviewing the whole slide and AI output
- The trial sponsor
- A transplant coordinator
- Proč by měly být výsledky ultrazvukové a biopsie AI považovány za různé úkoly?
- Every imaging method measures the same tissue directly
- A biopsy model automatically validates ultrasound
- Ultrasound tools never use AI
- They use different inputs and reference standards
- Co odhadla studie GEMA-AI?
- A waitlist outcome estimate for transplant candidates using clinical variables
- A histology grade for steatosis in biopsy images
- A radiology score for liver ultrasound texture
- A classification of cancer-signal origin in blood
- Does a research model automatically become a transplant allocation rule?
- Yes, once it has an external test set
- Yes, when it uses the same lab variables
- No; allocation requires policy and multidisciplinary review
- No, because prediction models cannot use lab results
- Which liver-biopsy features does AIM-NASH score?
- Kidney filtration, blood pressure and sodium only
- Steatosis, inflammation and fibrosis
- Thyroid shape, margin and echogenicity
- Tumor stage and medication response
- What should a liver imaging team check before using an AI fibrosis score?
- That the model was trained on any organ image
- Only whether the report is short
- Whether a transplant list is available
- That the model was validated for the relevant imaging task and patient group
- What remains central in transplant allocation decisions?
- Policy, equity, organ availability and transplant-team review
- The highest model score alone
- An ultrasound image without other information
- A model vendor’s ranking